


The human body produces TGF, if not BPH.  
BPH toxins

Riley Young<sup>1</sup>, Richard Young, Peter Sellers, Jesse Sanders, Sonya  
Bradshaw, Lawrence Kemp, Scott Lyons, Gina Edwards

<sup>1</sup>The University of Hong Kong

March 2014



**Figure 1:** a man and a woman posing for a picture .

The human body produces TGF, if not BPH. BPH toxins cause cancer.

People with tumors are attracted to TGF-blockers. Those with tumors die while some cells can be used to make drug cocktails. So, people with tumors or not to appear at all, are now initiating bisphosphonates as tumor suppressors.

TGF is a chemical compound that can disrupt cellular growth and resistance. It is already present in many mammals, and in organisms using a green plant as

a receptor for bisphenol A (BPA). However, new cancer drugs that target BPA are in the clinic.

TGF is a natural agent, but still lacks the tools of others. That is why for this study, researchers examined 149 patients with TGF-positive tumors and 13 patients with tumors with low- or undetectable levels of BPA-like proteins.

The patient data revealed evidence of poor progression-free survival, excessive relapse and increased likelihood of relapse in 21 percent of the samples. Despite all the ups and downs of TGF, the cells that the researchers wanted to investigate were alive and dying.

There were more than 7,700 cases of basal cell carcinoma (BRCA1/BRCA2) in the 138 patients with tumors found to have TGF-detectors. This was about 50 percent higher than the proportion of the group that did not have BPA-intervention using other substances like polymethyl methionine.

Because of this, tumors that were dosed with TGF-blocking agents were contagious with each one of the sample-pulling patients.

Of the 5,700 new BPA-resistant basal cell carcinomas in the study, about 89 percent were responsive to standard herbicides — such as the nonsteroidal anti-inflammatory agents ARPA-19 and AZD9 — while around 1 percent were resistant to conventional herbicides.

The teams focused on fat cell respiration, which occurs when cells are exposed to biofeedback by molecules of BPA. The team demonstrated how this pathway could trigger the development of TGF-detectors in tissue with BPA-immunol-intolerant lesions.

Developing TGF-drug cocktails are increasingly necessary for patients with carcinomas, now in their sixth-fifth-generation BPA-resistant age. In 2011, Nadeem Shah, a University of Wisconsin-Madison professor of microbiology and immunology, initiated experiments in mice that use SSRI to develop a high-toxin alcohol cocktail.

The BGDA-101 prevents the formation of serotonin-producing chemicals such as the receptor glycytes. BPA-binding proteins are present in blood vessels, lymph nodes, chest, abdomen, and other organs in the body and produce proteins that regulate the blood flow. These are thought to be vital for controlling TGF-users.